436 related articles for article (PubMed ID: 11053704)
1. Evidence that triglycerides are an independent coronary heart disease risk factor.
Cullen P
Am J Cardiol; 2000 Nov; 86(9):943-9. PubMed ID: 11053704
[TBL] [Abstract][Full Text] [Related]
2. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.
Ballantyne CM; Olsson AG; Cook TJ; Mercuri MF; Pedersen TR; Kjekshus J
Circulation; 2001 Dec; 104(25):3046-51. PubMed ID: 11748098
[TBL] [Abstract][Full Text] [Related]
3. Triglycerides and coronary risk.
Gaziano JM
Curr Cardiol Rep; 1999 Jul; 1(2):125-30. PubMed ID: 10980831
[TBL] [Abstract][Full Text] [Related]
4. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
5. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.
Onat A; Hergenç G; Sansoy V; Fobker M; Ceyhan K; Toprak S; Assmann G
Atherosclerosis; 2003 May; 168(1):81-9. PubMed ID: 12732390
[TBL] [Abstract][Full Text] [Related]
7. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
Isles CG; Paterson JR
QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
[TBL] [Abstract][Full Text] [Related]
8. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
Manninen V; Tenkanen L; Koskinen P; Huttunen JK; Mänttäri M; Heinonen OP; Frick MH
Circulation; 1992 Jan; 85(1):37-45. PubMed ID: 1728471
[TBL] [Abstract][Full Text] [Related]
9. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.
Gotto AM
Am Heart J; 2002 Dec; 144(6 Suppl):S33-42. PubMed ID: 12486414
[TBL] [Abstract][Full Text] [Related]
10. Diabetic dyslipidemia.
Kreisberg RA
Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol.
Rubins HB; Robins SJ; Iwane MK; Boden WE; Elam MB; Fye CL; Gordon DJ; Schaefer EJ; Schectman G; Wittes JT
Am J Cardiol; 1993 Jan; 71(1):45-52. PubMed ID: 8420235
[TBL] [Abstract][Full Text] [Related]
12. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
[TBL] [Abstract][Full Text] [Related]
13. Hypertriglyceridemia as a possible independent risk factor for stroke.
Lisak M; Demarin V; Trkanjec Z; Basić-Kes V
Acta Clin Croat; 2013 Dec; 52(4):458-63. PubMed ID: 24696996
[TBL] [Abstract][Full Text] [Related]
14. Triglyceride as a risk factor for coronary artery disease.
Gotto AM
Am J Cardiol; 1998 Nov; 82(9A):22Q-25Q. PubMed ID: 9819100
[TBL] [Abstract][Full Text] [Related]
15. The emergence of triglycerides as a significant independent risk factor in coronary artery disease.
Assmann G; Schulte H; Funke H; von Eckardstein A
Eur Heart J; 1998 Oct; 19 Suppl M():M8-14. PubMed ID: 9821011
[TBL] [Abstract][Full Text] [Related]
16. HDL and triglyceride as therapeutic targets.
Fruchart JC; Duriez P
Curr Opin Lipidol; 2002 Dec; 13(6):605-16. PubMed ID: 12441884
[TBL] [Abstract][Full Text] [Related]
17. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry.
Klempfner R; Erez A; Sagit BZ; Goldenberg I; Fisman E; Kopel E; Shlomo N; Israel A; Tenenbaum A
Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):100-8. PubMed ID: 26957517
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.
Nyman JA; Martinson MS; Nelson D; Nugent S; Collins D; Wittes J; Fye CL; Wilt TJ; Robins SJ; Bloomfield Rubins H;
Arch Intern Med; 2002 Jan; 162(2):177-82. PubMed ID: 11802751
[TBL] [Abstract][Full Text] [Related]
19. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
20. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
